UVIDI U METABOLIZAM I KLINIČKI ZNAČAJ VITAMINA K KOD UREMIJE: VIŠE OD SUPLEMENTA?
Sažetak
Vaskularna kalcifikacija (VK) je česta manifestacija pojačane kardiovaskularne bolesti, koja je primećena kod hronične bolesti bubrega (HBB). Iako je patogeneza kradiovaskularnih bolesti kompleksna, u poslednje vreme postalo je evidentno da je posledica disbalansa između promotera kalcifikacije i njenih inhibitora, u korist promotera kalcifikacije. Matriks Gla protein (MGP), moćan inhibitor vaskularne kalcifikacije, zavisi od vitamina K, kako bi bio aktiviran u potpunosti. Epidemiološki podaci sugerišu na to da je prevalencija deficita vitamina K visoka kod hronične bolesti bubrega, čak i u ranim fazama bolesti i u korelaciji je sa kardio-vaskularnim bolestima, kao posledicom. Kod životinja, suplementacijom vitanom K postignuta je regresija kardiovaskularne bolesti, pomoću aktivacije MGP. U ovom pregledu, cilj je da predstavimo postojeće podatke o efektima suplementacija vitamina K na vaskularnu kalcifikaciju i kardiovaskularne bolesti, kod bolesnika sa uremijom.
Reference
Bellinge JW, Dalgaard F, Murray K, Connolly E, Blekkenhorst LC, Bondonno CP, et al. Vitamin K Intake and atherosclerotic cardiovascular disease in the danish diet cancer and health study. Journal of the American Heart Association. 2021;10(16):e020551. [CrossRef] [PubMed]
Bostrom K, Tsao D, Shen S, Wang Y, Demer LL. Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem. 2001;276(17):14044-52. [CrossRef] [PubMed]
Brancaccio D, Biondi ML, Gallieni M, Turri O, Galassi A, Cecchini F, et al. Matrix GLA protein gene poly-morphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol. 2005;25(6):548-52. [CrossRef] [PubMed]
Caluwe R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS. Vitamin K2 supplementation in haemo-dialysis patients: a randomized dose-finding study. Nephrol Dial Transplant. 2014;29(7):1385-90. [CrossRef] [PubMed]
Card DJ, Shearer MJ, Schurgers LJ, Gomez K, Harrington DJ. What's in a name? The pharmacy of vitamin K. Br J Haematol. 2016;174(6):989-90. [CrossRef] [PubMed]
Cheung CL, Sahni S, Cheung BM, Sing CW, Wong IC. Vitamin K intake and mortality in people with chronic kidney disease from NHANES III. Clin Nutr. 2015; 34(2):235-40. [CrossRef] [PubMed]
Cranenburg EC, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Westerhuis R, et al. Vitamin K intake and status are low in hemodialysis patients. Kidney Int. 2012;82(5):605-10. [CrossRef] [PubMed]
Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, Vermeer C, Verschuren WM, Boer JM, et al. Circulating desphospho-uncarboxylated matrix gamma-carboxy-glutamate protein and the risk of coronary heart disease and stroke. J Thromb Haemost. 2014;12(7): 1028-34. [CrossRef] [PubMed]
Dalmeijer GW, van der Schouw YT, Vermeer C, Magdeleyns EJ, Schurgers LJ, Beulens JW. Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women. J Nutr Biochem. 2013;24(4):624-8. [CrossRef] [PubMed]
De Vriese AS, Caluwé R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, et al. Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemo-dialysis patients with atrial fibrillation: the Valkyrie Study. Journal of the American Society of Nephrology. 2020;31(1):186-96. [CrossRef] [PubMed]
Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, Medart L, et al. Dephosphorylated-un-carboxylated Matrix Gla protein concentration is pre-dictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis pa-tients. BMC Nephrol. 2014;15:145. [CrossRef] [PubMed]
Fain ME, Kapuku GK, Paulson WD, Williams CF, Raed A, Dong Y, et al. Inactive Matrix Gla Protein, Arterial Stiffness, and Endothelial Function in African American Hemodialysis Patients. Am J Hypertens. 2018. [CrossRef] [PubMed]
Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489-95. [CrossRef] [PubMed]
Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004;134(11):3100-5. [CrossRef] [PubMed]
Hashmath Z, Lee J, Gaddam S, Ansari B, Oldland G, Javaid K, et al. Vitamin K status, Warfarin use, and arterial stiffness in heart failure. Hypertension. 2019; 73(2):364-70. [CrossRef] [PubMed]
Holden RM, Booth SL, Day AG, Clase CM, Zimmerman D, Moist L, et al. Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease. Canadian journal of kidney health and disease. 2015;2(1):17. [CrossRef] [PubMed]
Hur DJ, Raymond GV, Kahler SG, Riegert-Johnson DL, Cohen BA, Boyadjiev SA. A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome. Am J Med Genet A. 2005;135(1):36-40. [CrossRef] [PubMed]
Kaesler N, Schreibing F, Speer T, de la Puente-Secades S, Rapp N, Drechsler C, et al. Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease. Kidney International. 2022;101(2):338-48. [CrossRef] [PubMed]
Keyzer CA, Vermeer C, Joosten MM, Knapen MH, Drummen NE, Navis G, et al. Vitamin K status and mortality after kidney transplantation: a cohort study. Am J Kidney Dis. 2018;65(3):474-83. [CrossRef] [PubMed]
Knapen MH, Braam LA, Drummen NE, Bekers O, Hoeks AP, Vermeer C. Menaquinone-7 supple-mentation improves arterial stiffness in healthy post-menopausal women. A double-blind randomised clini-cal trial. Thromb Haemost. 2015;113(5):1135-44. [CrossRef] [PubMed]
Krueger T, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, Jacobi J, et al. Vitamin K1 to slow vascular calcification in haemodialysis patients (Vita-VasK trial): a rationale and study protocol. Nephrol Dial Transplant. 2014;29(9):1633-8. [CrossRef] [PubMed]
Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, Kaczmarska M, Stefanczyk L, Vermeer C, et al. Effect of vitamin K2 on progression of atherosclerosis and vascular calcification in nondialyzed patients with chronic kidney disease stages 3-5. Pol Arch Med Wewn. 2015;125(9):631-40. [CrossRef] [PubMed]
Lees JS, Rankin AJ, Gillis KA, Zhu LY, Mangion K, Rutherford E, et al. The ViKTORIES trial: A rando-mized, double‐blind, placebo‐controlled trial of vitamin K supplementation to improve vascular health in kidney transplant recipients. American Journal of Transplantation. 2021. [CrossRef] [PubMed]
Levy-Schousboe K, Frimodt-Møller M, Hansen D, Peters CD, Kjærgaard KD, Jensen JD, et al. Vitamin K supplementation and arterial calcification in dialysis: results of the double-blind, randomised, placebo-con-trolled RenaKvit trial. Clinical Kidney Journal. 2021. [CrossRef] [PubMed]
Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386(6620):78-81. [CrossRef] [PubMed]
Mansour AG, Hariri E, Daaboul Y, Korjian S, El Alam A, Protogerou AD, et al. Vitamin K2 supplementation and arterial stiffness among renal transplant recipients-a single-arm, single-center clinical trial. J Am Soc Hypertens. 2017;11(9):589-97. [CrossRef] [PubMed]
McCabe KM, Booth SL, Fu X, Ward E, Adams MA, Holden RM. Vitamin K metabolism in a rat model of chronic kidney disease. American Journal of Nephro-logy. 2017;45(1):4-13. [CrossRef] [PubMed]
McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BM. Projecting ESRD incidence and pre-valence in the United States through 2030. Journal of the American Society of Nephrology. 2019;30(1): 127-35. [CrossRef] [PubMed]
Neradova A, Schumacher SP, Hubeek I, Lux P, Schurgers LJ, Vervloet MG. Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study. BMC Nephrol. 2017;18(1):149. [CrossRef] [PubMed]
Nimptsch K, Rohrmann S, Kaaks R, Linseisen J. Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). Am J Clin Nutr. 2010;91(5):1348-58. [CrossRef] [PubMed]
Oikonomaki T, Papasotiriou M, Ntrinias T, Kalogeropoulou C, Zabakis P, Kalavrizioti D, et al. The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: a 1-year follow-up randomized trial. Int Urol Nephrol. 2019. [CrossRef] [PubMed]
O'neill WC, Lomashvili KA. Recent progress in the treatment of vascular calcification. Kidney interna-tional. 2010;78(12):1232-9. [CrossRef] [PubMed]
Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010;152(10):640-8. [CrossRef] [PubMed]
Porter CJ, Stavroulopoulos A, Roe SD, Pointon K, Cassidy MJ. Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes. Nephrology Dialysis Transplantation. 2007;22(11): 3208-13. [CrossRef] [PubMed]
Puzantian H, Akers SR, Oldland G, Javaid K, Miller R, Ge Y, et al. Circulating Dephospho-Uncarboxylated Matrix Gla-Protein Is Associated With Kidney Dys-function and Arterial Stiffness. Am J Hypertens. 2018; 31(9):988-94. [CrossRef] [PubMed]
Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, et al. Cardiac calcification in adult hemo-dialysis patients: A link between end-stage renal disease and cardiovascular disease? Journal of the American College of Cardiology. 2002;39(4):695-701. [CrossRef] [PubMed]
Renal U. Data System. USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007.2011.
Rennenberg RJ, Kessels AG, Schurgers LJ, van Engelshoven JM, de Leeuw PW, Kroon AA. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag. 2009; 5(1):185-97. [CrossRef] [PubMed]
Riphagen IJ, Keyzer CA, Drummen NEA, de Borst MH, Beulens JWJ, Gansevoort RT, et al. Prevalence and Effects of Functional Vitamin K Insufficiency: The PREVEND Study. Nutrients. 2017;9(12). [CrossRef] [PubMed]
Roumeliotis A, Roumeliotis S, Panagoutsos S, Theodoridis M, Argyriou C, Tavridou A, et al. Carotid intima-media thickness is an independent predictor of all-cause mortality and cardiovascular morbidity in patients with diabetes mellitus type 2 and chronic kidney disease. Ren Fail. 2019;41(1):131-8. [CrossRef] [PubMed]
Roumeliotis S, Dounousi E, Salmas M, Eleftheriadis T, Liakopoulos V. Vascular Calcification in Chronic Kidney Disease: The Role of Vitamin K- Dependent Matrix Gla Protein. Front Med (Lausanne). 2020;7:154. [CrossRef] [PubMed]
Roumeliotis S, Mallamaci F, Zoccali C. Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update. J Clin Med. 2020;9(8). [CrossRef] [PubMed]
Roumeliotis S, Roumeliotis A, Dounousi E, Eleftheriadis T, Liakopoulos V. Biomarkers of vascular calcification in serum. Advances in clinical chemistry. 2020;98:91-147. [CrossRef] [PubMed]
Roumeliotis S, Roumeliotis A, Eleftheriadis T, Liakopoulos V. Letter to the Editor regarding "Six months vitamin K treatment does not affect systemic arterial calcification or bone mineral density in diabetes mellitus 2". European Journal of Nutrition. 2021:1-2. [CrossRef] [PubMed]
Roumeliotis S, Roumeliotis A, Gorny X, Mertens PR. Could Antioxidant Supplementation Delay Progression of Cardiovascular Disease in End-Stage Renal Disease Patients? Curr Vasc Pharmacol. 2021;19(1):41-54. [CrossRef] [PubMed]
Roumeliotis S, Roumeliotis A, Panagoutsos S, Giannakopoulou E, Papanas N, Manolopoulos VG, et al. Matrix Gla protein T-138C polymorphism is asso-ciated with carotid intima media thickness and pre-dicts mortality in patients with diabetic nephropathy. J Diabetes Complications. 2017;31(10):1527-32. [CrossRef] [PubMed]
Roumeliotis S, Roumeliotis A, Stamou A, Leivaditis K, Kantartzi K, Panagoutsos S, et al. The association of dp-ucMGP with cardiovascular morbidity and de-creased renal function in diabetic chronic kidney di-sease. International journal of molecular sciences. 2020;21(17):6035. [CrossRef] [PubMed]
Sabrina-Wong-Peixin Haroon B-C, Tai L-HL, Lynette Teo AD, Leon Schurgers B-WT, Priyanka Khatri C-CO, Sanmay Low X-EY, et al. Treatment to reduce vas-cular calcification in hemodialysis patients using vita-min K (Trevasc-HDK): a study protocol for a rando-mized controlled trial. Medicine. 2020;99(36). [CrossRef] [PubMed]
Schlieper G, Westenfeld R, Kruger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol. 2011; 22(2):387-95. [CrossRef] [PubMed]
Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol. 2010;5(4):568-75. [CrossRef] [PubMed]
Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost. 2008;100(4):593-603. [PubMed]
Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, Vermeer C, et al. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost. 2007;5(12): 2503-11. [CrossRef] [PubMed]
Schurgers LJ, Spronk HM, Soute BA, Schiffers PM, DeMey JG, Vermeer C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007;109(7):2823-31. [CrossRef] [PubMed]
Sheng K, Zhang P, Lin W, Cheng J, Li J, Chen J. Association of Matrix Gla protein gene (rs1800801, rs1800802, rs4236) polymorphism with vascular calci-fication and atherosclerotic disease: a meta-analysis. Sci Rep. 2017;7(1):8713. [CrossRef] [PubMed]
Thamratnopkoon S, Susantitaphong P, Tumkosit M, Katavetin P, Tiranathanagul K, Praditpornsilpa K, et al. Correlations of Plasma Desphosphorylated Uncarboxy-lated Matrix Gla Protein with Vascular Calcification and Vascular Stiffness in Chronic Kidney Disease. Nephron. 2017;135(3):167-72. [CrossRef] [PuMed]
Ueland T, Dahl CP, Gullestad L, Aakhus S, Broch K, Skardal R, et al. Circulating levels of non-pho-sphorylated undercarboxylated matrix Gla protein are associated with disease severity in patients with chro-nic heart failure. Clin Sci (Lond). 2011;121(3):119-27. [CrossRef] [PubMed]
Ueland T, Gullestad L, Dahl CP, Aukrust P, Aakhus S, Solberg OG, et al. Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J Intern Med. 2010;268(5):483-92. [CrossRef] [PubMed]
Van Ballegooijen AJ, Pilz S, Tomaschitz A, Grübler MR, Verheyen N. The synergistic interplay between vita-mins D and K for bone and cardiovascular health: a narrative review. International journal of endocrino-logy. 2017;2017. [CrossRef] [PubMed]
van den Heuvel EG, van Schoor NM, Lips P, Magdeleyns EJ, Deeg DJ, Vermeer C, et al. Circulating uncarboxylated matrix Gla protein, a marker of vitamin K status, as a risk factor of cardiovascular disease. Maturitas. 2014;77(2):137-41. [CrossRef] [PubMed]
Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2012;59(2):186-95. [CrossRef] [PubMed]
Witham MD, Lees JS, White M, Band M, Bell S, Chantler DJ, et al. Vitamin K supplementation to improve vascular stiffness in CKD: the K4Kidneys randomized controlled trial. Journal of the American Society of Nephrology. 2020;31(10):2434-45. [CrossRef] [PubMed]
Zebboudj AF, Imura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem. 2002;277(6):4388-94. [CrossRef] [PubMed]